Bush Jennifer sold $94K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 8,391 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 on 2026-09-03.

Original reporting
SEC EDGAR · Bush Jennifer
Published Sep 4, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for investors.

02

Market read

First‑report insider sale adds modest new information; limited trading relevance.

03

What to watch

The insider still holds a substantial position, indicating continued confidence.

Relevance 3/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

COO Jennifer Bush sold 8,391 shares for $93,606, reducing her stake to 329,529 shares.

Expected impact

modest short‑term price pressure

Evidence & confidence

The sale size is modest relative to market cap, but the insider remains a large holder, limiting downside risk.

Market effects

Biotech sector may see slight caution after insider sell.

US biotech equities could experience minor ripple.

Limited global impact.

Counterpoint

The sale could be routine liquidity for the executive, not a negative signal.

Key entities

  • Artiva Biotherapeutics, Inc.

    US‑listed biotech company (ticker ARTV).

  • Jennifer Bush

    Chief Operating Officer, Chief Legal Officer, and Compliance Officer of Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.